Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

NCT04678648 is registered in ClinicalTrials.gov with RasCal Therapeutics, Inc. as lead sponsor.

NCT NCT04678648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies
Lead sponsor
RasCal Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2021
Completion date
January 30, 2027
Enrollment
134 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, colon cancer, glioblastoma, lung cancer, pancreatic cancer, ras mutation